IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have been given an average rating of "Moderate Buy" by the sixteen research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $53.67.

A number of equities analysts have commented on IDYA shares. Oppenheimer restated an "outperform" rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. UBS Group started coverage on shares of IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a "buy" rating and a $50.00 target price on the stock. Leerink Partners downgraded shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Stifel Nicolaus increased their price objective on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the company a "buy" rating in a research note on Tuesday, September 10th. Finally, Wedbush reiterated an "outperform" rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Monday, November 4th.

Institutional Investors Weigh In On IDEAYA Biosciences

Institutional investors have recently bought and sold shares of the company. Allworth Financial LP raised its holdings in shares of IDEAYA Biosciences by 800.0% in the third quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after buying an additional 800 shares during the last quarter. Covestor Ltd raised its holdings in shares of IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company's stock worth $29,000 after buying an additional 922 shares during the last quarter. Quest Partners LLC purchased a new position in shares of IDEAYA Biosciences in the second quarter worth $41,000. US Bancorp DE raised its holdings in shares of IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after buying an additional 689 shares during the last quarter. Finally, Comerica Bank raised its holdings in shares of IDEAYA Biosciences by 723.5% during the first quarter. Comerica Bank now owns 1,507 shares of the company's stock worth $66,000 after purchasing an additional 1,324 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

IDEAYA Biosciences stock opened at $25.54 on Thursday. IDEAYA Biosciences has a 1-year low of $25.35 and a 1-year high of $47.74. The firm has a market capitalization of $2.21 billion, a P/E ratio of -10.96 and a beta of 0.86. The company's 50-day moving average is $30.79 and its 200 day moving average is $36.00.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.03. During the same quarter in the prior year, the company earned ($0.46) earnings per share. Research analysts anticipate that IDEAYA Biosciences will post -2.46 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.